NO20022528D0 - Kjemiske derivater og deres anvendelse som anti- telomerasemiddel - Google Patents

Kjemiske derivater og deres anvendelse som anti- telomerasemiddel

Info

Publication number
NO20022528D0
NO20022528D0 NO20022528A NO20022528A NO20022528D0 NO 20022528 D0 NO20022528 D0 NO 20022528D0 NO 20022528 A NO20022528 A NO 20022528A NO 20022528 A NO20022528 A NO 20022528A NO 20022528 D0 NO20022528 D0 NO 20022528D0
Authority
NO
Norway
Prior art keywords
chemical derivatives
telomerase agent
telomerase
agent
concerns
Prior art date
Application number
NO20022528A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022528L (no
Inventor
Patrick Mailliet
Jean-Francois Riou
Jean-Louis Mergny
Abdelazize Laoui
Francois Lavelle
Odile Patit-Genet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915031A external-priority patent/FR2801588B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20022528D0 publication Critical patent/NO20022528D0/no
Publication of NO20022528L publication Critical patent/NO20022528L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20022528A 1999-11-29 2002-05-28 Kjemiske derivater og deres anvendelse som anti- telomerasemiddel NO20022528L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915031A FR2801588B1 (fr) 1999-11-29 1999-11-29 Derives chimiques et leur application comme agent antitelomerase
FR0010561 2000-08-11
PCT/FR2000/003310 WO2001040218A1 (fr) 1999-11-29 2000-11-27 Derives arylamines et leur application comme agent antitelomerase

Publications (2)

Publication Number Publication Date
NO20022528D0 true NO20022528D0 (no) 2002-05-28
NO20022528L NO20022528L (no) 2002-05-28

Family

ID=26212577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022528A NO20022528L (no) 1999-11-29 2002-05-28 Kjemiske derivater og deres anvendelse som anti- telomerasemiddel

Country Status (27)

Country Link
EP (1) EP1244650B1 (sk)
JP (1) JP2003515604A (sk)
KR (1) KR20020058043A (sk)
CN (1) CN1402722A (sk)
AT (1) ATE243692T1 (sk)
AU (1) AU2179001A (sk)
BG (1) BG106753A (sk)
BR (1) BR0015992A (sk)
CA (1) CA2392507A1 (sk)
CO (1) CO5251431A1 (sk)
CZ (1) CZ20021849A3 (sk)
DE (1) DE60003583T2 (sk)
DK (1) DK1244650T3 (sk)
EA (1) EA200200616A1 (sk)
EE (1) EE200200263A (sk)
ES (1) ES2202206T3 (sk)
HU (1) HUP0204429A2 (sk)
IL (1) IL149402A0 (sk)
MX (1) MXPA02005276A (sk)
NO (1) NO20022528L (sk)
PE (1) PE20010912A1 (sk)
PL (1) PL355667A1 (sk)
PT (1) PT1244650E (sk)
SK (1) SK7402002A3 (sk)
UY (1) UY26456A1 (sk)
WO (1) WO2001040218A1 (sk)
YU (1) YU38102A (sk)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
US6977259B2 (en) 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
AU2001282268A1 (en) * 2000-08-08 2002-02-18 Aventis Pharma S.A. Phenantridine derivatives and their use as anti-telomerase agent
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
FR2822468B1 (fr) * 2001-03-23 2008-06-20 Aventis Pharma Sa Derives chimiques et leur application comme agent anti-telomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2003260472A1 (en) * 2002-09-10 2004-04-30 Pharmacia Italia S.P.A. Substituted pyridine derivatives as antitumor agent
WO2004037808A1 (en) * 2002-10-24 2004-05-06 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
CA2546727C (en) * 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
WO2007049057A2 (en) * 2005-10-28 2007-05-03 Iti Scotland Limited Novel fluorescent dyes and uses thereof
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
KR100761869B1 (ko) * 2006-07-07 2007-10-04 김현기 트리아진 유도체 화합물 및 이를 포함하는 암 치료용조성물
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
JP5325517B2 (ja) * 2007-10-12 2013-10-23 住友化学株式会社 ジベンゾオキセピン化合物の精製方法
JP2009102249A (ja) * 2007-10-22 2009-05-14 Sumitomo Chemical Co Ltd ジベンゾオキセピン化合物の結晶の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6156763A (en) * 1998-02-04 2000-12-05 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
DE19812879A1 (de) * 1998-03-24 1999-09-30 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine

Also Published As

Publication number Publication date
WO2001040218A1 (fr) 2001-06-07
PE20010912A1 (es) 2001-09-01
PL355667A1 (en) 2004-05-04
ATE243692T1 (de) 2003-07-15
JP2003515604A (ja) 2003-05-07
BG106753A (bg) 2003-02-28
BR0015992A (pt) 2002-08-06
YU38102A (sh) 2004-12-31
MXPA02005276A (es) 2002-11-07
CA2392507A1 (fr) 2001-06-07
EP1244650B1 (fr) 2003-06-25
UY26456A1 (es) 2001-06-29
CZ20021849A3 (cs) 2002-08-14
DK1244650T3 (da) 2003-10-20
EE200200263A (et) 2003-06-16
DE60003583T2 (de) 2004-05-13
CN1402722A (zh) 2003-03-12
EP1244650A1 (fr) 2002-10-02
NO20022528L (no) 2002-05-28
EA200200616A1 (ru) 2002-10-31
HUP0204429A2 (hu) 2003-04-28
SK7402002A3 (en) 2002-11-06
IL149402A0 (en) 2002-11-10
ES2202206T3 (es) 2004-04-01
CO5251431A1 (es) 2003-02-28
PT1244650E (pt) 2003-11-28
AU2179001A (en) 2001-06-12
DE60003583D1 (de) 2003-07-31
KR20020058043A (ko) 2002-07-12

Similar Documents

Publication Publication Date Title
NO20022528D0 (no) Kjemiske derivater og deres anvendelse som anti- telomerasemiddel
ATE302775T1 (de) Carbolinderivate
WO2002096903A3 (fr) Derives chimiques et leur application comme agent antitelomerase
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
ATE346067T1 (de) Carbolinderivate
ATE231872T1 (de) Thiazolopyrimidinderivate
MXPA03002911A (es) Compuestos quimicos.
NO20025150D0 (no) 2-acylindolderivater og deres anvendelse som antitumormidler
MXPA02012076A (es) Compuestos quimicos.
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
MXPA02012659A (es) Derivados de pirazindiona condensados.
SE0101932D0 (sv) Pharmaceutical combinations
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
SE9904377D0 (sv) Pharmaceutical combinations
DE60112960D1 (de) Kondensierte pyridoindolderivate
DE60315288D1 (de) Cyanoguanidin prodrugs
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
MXPA02012472A (es) Compuestos quimicos.
DE60213798D1 (de) Carbolinderivate als pdev inhibitoren
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
DK1453783T3 (da) Substituerede arylcycloalkaner og deres anvendelse som anticancermidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application